Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 128 of the 130 references it cites were found in a registry or an index; 51 of the 84 sources its claims cite were checked for support.

Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation

Open access
Dhoundiyal, Shivang, Srivastava, Shriyansh, Kumar, Sachin, Singh, Gaaminepreet, Ashique, Sumel, Pal, Radheshyam, Mishra, Neeraj, Taghizadeh-Hesary, Farzad · 2024 · European Journal of Medical Research

Abstract

This review explores radiopharmaceuticals, targeted delivery, theranostics, imaging and therapeutic innovation, with attention to safety considerations.

Overview

CoChat Summary

## TL;DR

This is a narrative review of radiopharmaceuticals, covering how radiolabelling, targeted delivery, imaging, theranostics, safety, nanoparticles, and future AI-enabled approaches are reshaping precision medicine. It argues that radiopharmaceuticals can improve diagnostic accuracy and treatment specificity while reducing off-target effects, with case examples showing survival benefits in several cancers.

## Key findings

  • The review highlights three targeted delivery strategies: passive targeting via the enhanced permeability and retention effect, active ligand-receptor targeting, and stimulus-responsive release systems.
  • In the VISION phase III trial, ^177Lu-PSMA-617 plus standard care in PSMA-positive mCRPC increased median overall survival from 11.3 to 15.3 months and median radiographic progression-free survival from 3.4 to 8.7 months.
  • In the ALSYMPCA phase III trial, ^223Ra-dichloride in castration-resistant prostate cancer with bone metastases increased median overall survival from 11.3 to 14.9 months and median time to first symptomatic skeletal event from 9.8 to 15.6 months.
  • In a phase II neuroblastoma trial, ^131I-MIBG with chemotherapy and stem cell rescue improved 3-year event-free survival from 48% to 61% and 3-year overall survival from 59% to 74%.
  • The paper emphasizes that radiopharmaceuticals are moving toward theranostics, where the same agent supports both imaging and therapy, and that AI may improve image analysis, staging, and treatment planning.

## Methods

  • Narrative review of the radiopharmaceuticals field, organized around targeted drug delivery, imaging and theranostics, safety, next-generation formulations, case studies, and future directions.
  • Uses published examples and clinical trials as illustrative case studies, including PSMA-targeted therapy in prostate cancer, PRRT in neuroendocrine tumors, bone-targeted agents, and neuroblastoma radiopharmaceuticals.
  • Main analysis is qualitative and descriptive; the paper synthesizes prior literature rather than reporting a new experimental dataset or statistical model.

## Limitations

  • The paper does not state formal limitations explicitly.
  • Evident from the text: it is a broad narrative review, so its claims are largely synthesis-based rather than derived from a systematic review or original study.
  • Evident from the text: many sections are highly general and descriptive, with limited critical comparison of opposing evidence or detailed methodological appraisal of the cited studies.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s40001-023-01627-0

Cites

128 of 128 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Radiotherapy response on resistant and non-resistant cancer patients
Fig. 1 Radiotherapy response on resistant and non-resistant cancer patientsCC BY · PubMed Central
Fig. 2 Current strategies and Radiopharmaceuticals application in theranostics
Fig. 2 Current strategies and Radiopharmaceuticals application in theranosticsCC BY · PubMed Central
Fig. 3 Radioligand therapy for metastatic prostate cancer treatment
Fig. 3 Radioligand therapy for metastatic prostate cancer treatmentCC BY · PubMed Central
Fig. 4 Forecast of the global pharmaceutical market from the year 2022–2032
Fig. 4 Forecast of the global pharmaceutical market from the year 2022–2032CC BY · PubMed Central

Verification

Claims the paper makes

43 Valid · 7 Not valid · 33 Not checked · 18 Own results and interpretations

64 more claims · 32 with their cited sources checked

Create a free account to see all 101 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 28
  • Probably not a substantial claim. 8

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Self-check results appear here once an independent check has confirmed them.

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

1 of 1

Citations

Cites

1 retracted

Show all 130 references

Research works printed but not linked: 1

  1. Sarkar PS. Safety, regulations, metrology and standards in neutron imaging. In: Kashyap YS, Aswal DK, Sarkar PS, editors. Neutron imaging: basics, techniques and applications. Singapore: Springer Singapore; 2022.

Cited by

See all 144

Metadata

Authors
Dhoundiyal, S., Srivastava, S., Kumar, S., Singh, G., Ashique, S., Pal, R., Mishra, N., & Taghizadeh-Hesary, F.
Affiliations
  • Galgotias University (IN)
  • Delhi Pharmaceutical Science and Research University (IN)
  • Case Western Reserve University (US)
  • Amity University Madhya Pradesh (IN)
Corresponding author
Srivastava, Shriyansh
Venue
European Journal of Medical Research
Published
2024-01-05
Volume
29
Issue
1
Pages
26-26
ISSN
  • 0949-2321 (ISSN-L)
  • 2047-783X
OpenAlex
W4390632397
Cited by
144
References
130
Citations by year
2026: 36 · 2025: 64 · 2024: 44
FWCI
9.31
Type
journal article
Language
en
Open access
Licence
Locations
  • European journal of medical research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords
radiopharmaceuticals, targeted drug delivery, enhanced permeability and retention effect, ligand-receptor targeting, stimuli-responsive drug release, theranostics, diagnostic imaging, radiolabeled antibodies, peptide receptor radionuclide therapy, neuroendocrine tumors, bone metastasis, nanoparticle formulation, precision medicine, artificial intelligence, radionuclides
MeSH terms
Artificial Intelligence, Humans, Radiopharmaceuticals, Precision Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation. https://app.cochat.ai/papers/10.1186/s40001-023-01627-0
The paper
Dhoundiyal, S., Srivastava, S., Kumar, S., Singh, G., Ashique, S., Pal, R., Mishra, N., & Taghizadeh-Hesary, F. (2024). Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation. European Journal of Medical Research. https://doi.org/10.1186/s40001-023-01627-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.